Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Sales, ordinary profit and interim net income attributable to owners of the parent exceeded the year-earlier period, due mainly to growth in sales volumes in the core ischemic heart disease, cardiac rhythm management and cardiovascular surgery businesses, as well as growth in medical device-related sales.
None
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥51,600 million (YoY +18.0%) |
| Operating profit | ¥2,065 million (YoY +40.9%) |
| Ordinary income | ¥2,104 million (YoY +41.7%) |
| Profit attributable to owners of the parent | ¥1,398 million (YoY +38.1%) |
| Net income per share | ¥50.87 |
| Equity ratio | End of the current fiscal period 44.7 / End of previous period 46 |
| Total assets | ¥51,902 million |
| Net assets | ¥23,195 million |
| Cash flows from operating activities | ¥22,874 thousand |
| Cash flows from investing activities | ¥-197,995 thousand |
| Cash flows from financing activities | ¥-1,489,620 thousand |
| Cash and cash equivalents at end of period | ¥9,267,001 thousand |
| Full-year earnings forecast | Net Sales ¥100,000 million (YoY +10.6%) / Operating profit ¥3,350 million (YoY +10.9%) / Ordinary income ¥3,380 million (YoY +10.4%) / Net income ¥2,210 million (YoY +4.3%) |
| Annual Dividend Forecast | 54 yen → 55 yen（+1.9%） |
| Segment revenue | Ischemic heart disease-related ¥10,444,925 thousand (YoY +7.5%), Cardiac rhythm management-related ¥13,875,289 thousand (YoY +11.7%), Cardiovascular surgery-related ¥8,212,370 thousand (YoY +8.8%), Peripheral vascular disease-related and neurosurgery-related ¥5,329,231 thousand (YoY +18.4%), Medical equipment-related businesses ¥7,232,985 thousand (YoY +91.1%), Other ¥6,505,629 thousand (YoY +12.8%) |
| Depreciation and amortization | ¥177,862 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥2,505 thousand / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | None |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name Not applicable |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No (earnings presentation video distributed) |
| Issued Shares at Period-End | 30,503,310 |
| Treasury Shares at Period-End | 3,008,974 |
| Factors Behind Changes in Business Performance | Sales, ordinary profit and interim net income attributable to owners of the parent exceeded the year-earlier period, due mainly to growth in sales volumes in the core ischemic heart disease, cardiac rhythm management and cardiovascular surgery businesses, as well as growth in medical device-related sales. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This was due to growth in sales volumes in the core ischemic heart disease, cardiac rhythm management and cardiovascular surgery businesses, as well as growth in medical device-related sales. The company also worked to deepen relationships with existing customers, acquire new customers, propose capital investment projects and expand its product range.